bluebird bio, Inc. (NASDAQ:BLUE) PT Raised to $163.00

bluebird bio, Inc. (NASDAQ:BLUE) had its price target boosted by stock analysts at SunTrust Banks, Inc. from $108.00 to $163.00 in a research note issued on Friday, November 3rd. The brokerage currently has a “buy” rating on the biotechnology company’s stock. SunTrust Banks, Inc.’s price objective would indicate a potential downside of 2.51% from the company’s current price.

Several other analysts also recently commented on BLUE. Jefferies Group LLC reissued a “buy” rating and set a $88.00 price objective on shares of bluebird bio in a research report on Friday, August 11th. BMO Capital Markets restated a “buy” rating and set a $108.00 target price on shares of bluebird bio in a research note on Friday, August 4th. Goldman Sachs Group, Inc. (The) restated a “buy” rating and set a $186.00 target price on shares of bluebird bio in a research note on Friday, October 6th. Maxim Group restated a “buy” rating and set a $170.00 target price (up previously from $100.00) on shares of bluebird bio in a research note on Monday, October 9th. Finally, BTIG Research upgraded shares of bluebird bio from a “neutral” rating to a “buy” rating and set a $177.00 target price on the stock in a research note on Thursday, November 2nd. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and fourteen have assigned a buy rating to the company. bluebird bio currently has a consensus rating of “Buy” and a consensus price target of $131.05.

Shares of bluebird bio (NASDAQ:BLUE) traded down $0.05 on Friday, hitting $167.20. 363,723 shares of the stock were exchanged, compared to its average volume of 835,570. bluebird bio has a 1 year low of $56.80 and a 1 year high of $169.60.

bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.68) by ($0.05). The company had revenue of $7.71 million for the quarter, compared to analysts’ expectations of $8.47 million. bluebird bio had a negative net margin of 883.18% and a negative return on equity of 28.79%. The firm’s revenue for the quarter was up 397.4% compared to the same quarter last year. During the same period in the previous year, the firm posted ($2.07) earnings per share. research analysts predict that bluebird bio will post -6.68 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “bluebird bio, Inc. (NASDAQ:BLUE) PT Raised to $163.00” was originally reported by BBNS and is owned by of BBNS. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://baseballnewssource.com/markets/bluebird-bio-inc-blue-price-target-raised-to-163-00-at-suntrust-banks-inc/1756998.html.

In related news, insider Jeffrey T. Walsh sold 9,900 shares of the firm’s stock in a transaction on Friday, November 10th. The shares were sold at an average price of $149.58, for a total value of $1,480,842.00. Following the completion of the transaction, the insider now directly owns 28,798 shares of the company’s stock, valued at $4,307,604.84. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Daniel Lynch sold 500 shares of the firm’s stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $120.00, for a total transaction of $60,000.00. Following the completion of the transaction, the director now directly owns 3,300 shares of the company’s stock, valued at $396,000. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 193,168 shares of company stock valued at $25,558,003. Insiders own 3.90% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Hanseatic Management Services Inc. lifted its position in bluebird bio by 0.3% in the second quarter. Hanseatic Management Services Inc. now owns 10,436 shares of the biotechnology company’s stock worth $1,096,000 after buying an additional 27 shares during the last quarter. Teacher Retirement System of Texas lifted its position in shares of bluebird bio by 1.7% during the second quarter. Teacher Retirement System of Texas now owns 3,250 shares of the biotechnology company’s stock worth $341,000 after purchasing an additional 53 shares during the last quarter. Cornerstone Capital Management Holdings LLC. lifted its position in shares of bluebird bio by 0.8% during the second quarter. Cornerstone Capital Management Holdings LLC. now owns 17,955 shares of the biotechnology company’s stock worth $1,885,000 after purchasing an additional 140 shares during the last quarter. Prudential Financial Inc. lifted its position in shares of bluebird bio by 4.0% during the second quarter. Prudential Financial Inc. now owns 3,882 shares of the biotechnology company’s stock worth $408,000 after purchasing an additional 150 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its position in shares of bluebird bio by 0.5% during the second quarter. The Manufacturers Life Insurance Company now owns 31,433 shares of the biotechnology company’s stock worth $3,302,000 after purchasing an additional 151 shares during the last quarter.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Analyst Recommendations for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan
Shohei Ohtani Has Turned Down Red Sox and Yankees
Shohei Ohtani Has Turned Down Red Sox and Yankees
Free Agency Season Has Finally Heated Up
Free Agency Season Has Finally Heated Up


Leave a Reply

 
© 2006-2017 BBNS.